Comparative Pharmacology
Head-to-head clinical analysis: METHIMAZOLE versus THYRO BLOCK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHIMAZOLE versus THYRO BLOCK.
METHIMAZOLE vs THYRO-BLOCK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones (T3 and T4). Also inhibits peripheral conversion of T4 to T3.
THYRO-BLOCK (potassium iodide) inhibits thyroid hormone synthesis and release by blocking the oxidation of iodide to iodine, thereby preventing the incorporation of iodine into thyroglobulin. It also reduces the vascularity of the thyroid gland.
Oral, initial dose 15-40 mg daily in 3 divided doses; maintenance dose 5-15 mg daily
Oral, 120 mg every 12 hours (total daily dose 240 mg) starting 24 hours before exposure to radioactive iodine and continuing for 5–10 days as directed.
None Documented
None Documented
Clinical Note
moderateMethimazole + Prednisolone
"The serum concentration of Prednisolone can be decreased when it is combined with Methimazole."
Clinical Note
moderateMethimazole + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Methimazole resulting in a loss in efficacy."
Clinical Note
moderateMethimazole + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole."
Clinical Note
moderate4-6 hours in euthyroid patients; prolonged to 10-15 hours in hyperthyroid patients. Clinical context: steady-state achieved in 2-3 days, but therapeutic effect on thyroid hormone synthesis requires 3-8 weeks due to depletion of stored hormones.
Terminal elimination half-life is approximately 36 hours (range 24-48 hours) in euthyroid patients; prolonged in hyperthyroid patients due to increased thyroid hormone binding and reduced clearance.
Primarily renal (65-70% as unchanged drug and metabolites), with minor biliary/fecal elimination (<10%).
Primarily renal excretion of unchanged drug (80-90% of absorbed dose) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category D/X
Category C
Antithyroid Agent
Antithyroid Agent
Methimazole + Clozapine
"The risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine."